Interim Guidelines for Pregnant Women During a Zika Virus Outbreak — United States, 2016

Emily E. Petersen, MD1; J. Erin Staples, MD, PhD2; Dana Meaney-Delman, MD3; Marc Fischer, MD2; Sascha R. Ellington, MSPH1; William M. Callaghan, MD1; Denise J. Jamieson, MD1

On January 19, 2016, this report was posted as an MMWR Early Release on the MMWR website (http://www.cdc.gov/mmwr).

CDC has developed interim guidelines for health care providers in the United States caring for pregnant women during a Zika virus outbreak. These guidelines include recommendations for pregnant women considering travel to an area with Zika virus transmission and recommendations for screening, testing, and management of pregnant returning travelers. Updates on areas with ongoing Zika virus transmission are available online (http://wwwnc.cdc.gov/travel/notices/). Health care providers should ask all pregnant women about recent travel. Pregnant women with a history of travel to an area with Zika virus transmission and who report two or more symptoms consistent with Zika virus disease (acute onset of fever, maculopapular rash, arthralgia, or conjunctivitis) during or within 2 weeks of travel, or who have ultrasound findings of fetal microcephaly or intracranial calcifications, should be tested for Zika virus infection in consultation with their state or local health department. Testing is not indicated for women without a travel history to an area with Zika virus transmission. In pregnant women with laboratory evidence of Zika virus infection, serial ultrasound examination should be considered to monitor fetal growth and anatomy and referral to a maternal-fetal medicine or infectious disease specialist with expertise in pregnancy management is recommended. There is no specific antiviral treatment for Zika virus; supportive care is recommended.

Zika virus is a mosquito-borne flavivirus transmitted primarily by *Aedes aegypti* mosquitoes (1,2). These vectors also transmit dengue and chikungunya virus and are found throughout much of the Americas, including parts of the United States. An estimated 80% of persons infected with Zika virus are asymptomatic (2,3). Symptomatic disease is generally mild and characterized by acute onset of fever, maculopapular rash, arthralgia, or nonpurulent conjunctivitis. Symptoms usually last from several days to 1 week. Severe disease requiring hospitalization is uncommon, and fatalities are rare. Guillain-Barré syndrome has been reported in patients following suspected Zika virus infection (4–6).

Pregnant women can be infected with Zika virus in any trimester (4,7,8). The incidence of Zika virus infection in pregnant women is not currently known, and data on pregnant women infected with Zika virus are limited. No evidence exists to suggest that pregnant women are more susceptible to Zika virus infection or experience more severe disease during pregnancy.

Maternal-fetal transmission of Zika virus has been documented throughout pregnancy (4,7,8). Although Zika virus RNA has been detected in the pathologic specimens of fetal losses (4), it is not known if Zika virus caused the fetal losses. Zika virus infections have been confirmed in infants with microcephaly (4), and in the current outbreak in Brazil, a marked increase in the number of infants born with microcephaly has been reported (9). However, it is not known how many of the microcephaly cases are associated with Zika virus infection. Studies are under way to investigate the association of Zika virus infection and microcephaly, including the role of other contributory factors (e.g., prior or concurrent infection with other organisms, nutrition, and environment). The full spectrum of outcomes that might be associated with Zika virus infections during pregnancy is unknown and requires further investigation.

Recommendations for Pregnant Women Considering Travel to an Area of Zika Virus Transmission

Because there is neither a vaccine nor prophylactic medications available to prevent Zika virus infection, CDC recommends that all pregnant women consider postponing travel to areas where Zika virus transmission is ongoing (10). If a pregnant woman travels to an area with Zika virus transmission, she should be advised to strictly follow steps to avoid mosquito bites (11,12). Mosquitoes that spread Zika virus bite both indoors and outdoors, mostly during the daytime; therefore, it is important to ensure protection from mosquitoes throughout the entire day (13). Mosquito prevention strategies include wearing long-sleeved shirts and long pants, using U.S. Environmental Protection Agency (EPA)–registered insect repellents, using permethrin-treated clothing and gear, and staying and sleeping in screened-in or air-conditioned rooms. When used as directed on the product label, insect repellents containing DEET, picaridin, and IR3535 are safe for pregnant women (14,15). Further guidelines for using insect repellents are available online (http://wwwnc.cdc.gov/travel/page/avoid-bug-bites) (11,15).
Recommendations for Pregnant Women with History of Travel to an Area of Zika Virus Transmission

Health care providers should ask all pregnant women about recent travel. Women who traveled to an area with ongoing Zika virus transmission during pregnancy should be evaluated for Zika virus infection and tested in accordance with CDC Interim Guidance (Figure). Because of the similar geographic distribution and clinical presentation of Zika, dengue, and chikungunya virus infection, patients with symptoms consistent with Zika virus disease should also be evaluated for dengue and chikungunya virus infection, in accordance with existing guidelines (16,17).

Zika virus testing of maternal serum includes reverse transcription-polymerase chain reaction (RT-PCR) testing for symptomatic patients with onset of symptoms within the previous week. Immunoglobulin M (IgM) and neutralizing antibody testing should be performed on specimens collected ≥4 days after onset of symptoms. Cross-reaction with related flaviviruses (e.g., dengue or yellow fever) is common with antibody testing, and thus it might be difficult to distinguish Zika virus infection from other flavivirus infections. Consultation with state or local health departments might be necessary to assist with interpretation of results (18). Testing of asymptomatic pregnant women is not recommended in the absence of fetal microcephaly or intracranial calcifications.

Zika virus RT-PCR testing can be performed on amniotic fluid (7,9). Currently, it is unknown how sensitive or specific this test is for congenital infection. Also, it is unknown if a positive result is predictive of a subsequent fetal abnormality, and if so, what proportion of infants born after infection will have abnormalities. Amniocentesis is associated with an overall 0.1% risk of pregnancy loss when performed at less than 24 weeks of gestation. Immunoglobulin M (IgM) and neutralizing antibody testing should be performed on specimens collected ≥4 days after onset of symptoms. Cross-reaction with related flaviviruses (e.g., dengue or yellow fever) is common with antibody testing, and thus it might be difficult to distinguish Zika virus infection from other flavivirus infections. Consultation with state or local health departments might be necessary to assist with interpretation of results (18). Testing of asymptomatic pregnant women is not recommended in the absence of fetal microcephaly or intracranial calcifications.

FIGURE. Interim guidance: testing algorithm* for a pregnant woman with history of travel to an area¶ with Zika virus transmission, with or without clinical illness** consistent with Zika virus disease

---

* Availability of Zika virus testing is limited; consult your state or local health department to facilitate testing. Tests include Zika virus reverse transcription–polymerase chain reaction (RT-PCR) and Zika virus immunoglobulin M (IgM) and neutralizing antibodies on serum specimens. Given the overlap of symptoms and endemic areas with other viral illnesses, evaluate for possible dengue or chikungunya virus infection.
† Laboratory evidence of maternal Zika virus infection: 1) Zika virus RNA detected by RT-PCR in any clinical specimen; or 2) positive Zika virus IgM with confirmatory neutralizing antibody titers that are ≥4-fold higher than dengue virus neutralizing antibody titers in serum. Testing would be considered inconclusive if Zika virus neutralizing antibody titers are <4-fold higher than dengue virus neutralizing antibody titers.
§ Amniocentesis is not recommended until after 15 weeks of gestation. Amniotic fluid should be tested for Zika virus RNA by RT-PCR.
¶ Updates on areas with ongoing Zika virus transmission are available online (http://wwwnc.cdc.gov/travel/notices/).
** Clinical illness is consistent with Zika virus disease if two or more symptoms (acute onset of fever, maculopapular rash, arthralgia, or conjunctivitis) are present.
gestation (19). Amniocentesis performed ≥15 weeks of gesta-
tion is associated with lower rates of complications than those
performed at earlier gestational ages, and early amniocentesis
(≤14 weeks of gestation) is not recommended (20). Health care
providers should discuss the risks and benefits of amniocentesis
with their patients. A positive RT-PCR result on amniotic fluid
would be suggestive of intrauterine infection and potentially
useful to pregnant women and their health care providers (20).

For a live birth with evidence of maternal or fetal Zika virus
infection, the following tests are recommended: histopatho-
logic examination of the placenta and umbilical cord; testing
of frozen placental tissue and cord tissue for Zika virus RNA;
and testing of cord serum for Zika and dengue virus IgM
and neutralizing antibodies. CDC is developing guidelines
for infants infected by Zika virus. If a pregnancy results in a
fetal loss in a woman with history of travel to an area of Zika
disease during or within 2 weeks of travel or findings of fetal
microcephaly, Zika virus RT-PCR and immunohistochemical
staining should be performed on fetal tissues, including
umbilical cord and placenta.

There is no commercially available test for Zika virus. Testing
for Zika virus infection is performed at CDC and several state
health departments. Health care providers should contact their
state or local health department to facilitate testing and for
assistance with interpreting results (4).

How to Treat Pregnant Women with Diagnoses of
Zika Virus Disease

No specific antiviral treatment is available for Zika virus
disease. Treatment is generally supportive and can include rest,
fluids, and use of analgesics and antipyretics (4). Fever should
be treated with acetaminophen (27). Although aspirin and
other nonsteroidal anti-inflammatory drugs are not typically
used in pregnancy, these medications should specifically be
avoided until dengue can be ruled out to reduce the risk for
hemorrhage (4,9,17).

In pregnant a woman with laboratory evidence of Zika
virus in serum or amniotic fluid, serial ultrasounds should be
considered to monitor fetal anatomy and growth every
3–4 weeks. Referral to a maternal-fetal medicine or infectious
disease specialist with expertise in pregnancy management is
recommended.

References

http://dx.doi.org/10.3201/eid1509.090442.
2. CDC. Zika virus. Atlanta, GA: US Department of Health and Human
3. Duffy MR, Chen TH, Hancock WT, et al. Zika virus outbreak on Yap
http://dx.doi.org/10.1056/NEJMoa0805715.
4. CDC. CDC health advisory: recognizing, managing, and reporting Zika
virus infections in travelers returning from Central America, South
America, the Caribbean and Mexico. Atlanta, GA: US Department of
Health and Human Services, CDC; 2016. http://emergency.cdc.gov/
han/han00385.asp.
5. Oehler E, Wattrin L, Larre P, et al. Zika virus infection complicated by
Guillain-Barre syndrome—case report, French Polynesia, December
6. Musso D, Nilles EJ, Cao-Lormeau VM. Rapid spread of emerging Zika
http://dx.doi.org/10.1111/1469-0691.12707.
7. Besnard M, Lastere S, Teissier A, Cao-Lormeau V, Musso D. Evidence of
perinatal transmission of Zika virus, French Polynesia, December
S, Bispo de Filippis AM. Zika virus intrauterine infection causes fetal
brain abnormality and microcephaly: tip of the iceberg? Ultrasound
assessment. Zika virus epidemic in the Americas: potential association
with microcephaly and Guillain-Barre syndrome. Stockholm, Sweden:
with-microcephaly-rapid-risk-assessment.pdf.
10. CDC. Travelers’ health. CDC issues interim travel guidance related to
Zika virus for 14 countries and territories in Central and South America
and the Caribbean. Atlanta, GA: US Department of Health and Human
11. CDC. Travelers’ health: avoid bug bites. Atlanta, GA: US Department
travel/page/avoid-bug-bites.
12. CDC. Zika virus: prevention. Atlanta, GA: US Department of Health
index.html.
13. Schaffner F, Mathis A. Dengue and dengue vectors in the WHO European
region: past, present, and scenarios for the future. Lancet Infect Dis
cdc.gov/westnile/faq repellent.html.
15. CDC. Travelers’ health: protection against mosquitoes, ticks, & other
arthropods. Atlanta, GA: US Department of Health and Human Services,
protection-against-mosquitoes-ticks-other-arthropods.
16. CDC. Chikungunya virus: clinical evaluation & disease. Atlanta, GA:
17. World Health Organization. Dengue: guidelines for diagnosis, treatment,
18. CDC. Zika virus. For health care providers: diagnostic testing. Atlanta,

1Division of Reproductive Health, National Center for Chronic Disease
Prevention and Health Promotion, CDC. 2Arboviral Diseases Branch, National
Center for Emerging and Zoonotic Infectious Diseases, CDC. 3Office of the
Director, National Center for Emerging and Zoonotic Infectious Diseases, CDC.
Corresponding author: Denise Jamieson, djj0@cdc.gov, 770-488-6377.
